Lack of effect of bumetanide on body potassium content in hypertension.
1 Twelve patients with mild hypertension were treated with bumetanide for a six-month period. No evidence was found of hypokalaemia or decreased total exchangeable potassium in subjects with or without additional potassium supplements. 2 Bumetanide was well tolerated by all patients. It caused hyperuricaemia but no episodes of gout occurred. Minor abnormalities of liver function were noted. 3 Bumetanide did not have a sustained antihypertensive action.
D000328:Adult; D001823:Body Composition / Q000187:drug effects*; D002034:Bumetanide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004232:Diuretics / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000032:analysis* / Q000097:blood
D004232:Diuretics; D002034:Bumetanide; D011188:Potassium